But not until Novo Nordisk finds a way to make sufficient money off of it to replace their soon-to-be useless insulin production.
The researchers are using a single factor rodent diabetes knock-out model that in no way resembles the multifactorial human diabetes condition. The injected FGF1 protein simply restores the knocked-out gene function and the non-diabetic status in the now “non-knocked-out” rodent. This is a play toy that allows researchers to explore interesting secondary gene functions related to the diabetes condition. It has no implications for resolving diabetes in humans.